CARLSBAD, Calif., Feb. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Repla ...

Ionis Pharmaceuticals (IONS) reported a loss of 6 cents per share for fourth-quarter 2023, which was significantly narrower than the Zacks Consensus Estimate of a loss of 78 cents per share.The bottom line includes compensation expenses related to equity awards. Excluding these special items, adjusted earnings per share were 12 cents against a loss of $1.18 per share in the year-ago quarter.Total revenues were $325 million in the fourth quarter, which beat the Zacks Consensus Estimate of $184.0 million. Rev ...

February 21, 2024 On Today's Earnings Call Brett Monia, Ph.D. Chief Executive Officer Beth Hougen Chief Financial Officer Eugene Schneider, M.D. Chief Clinical Development Officer IONIS 3 In this presentation, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries. Introduction Brett Monia, Ph.D. Chief Executive Officer Key Achievements in the Last 12 Months Bepirovirsen (HBV) IONIS-FB-LRx (IgAN) FDA Approvals1 Positive Phase 3 R ...

Company Participants Wade Walke - Senior Vice President, Investor Relations Eugene Schneider - Clinical Chief Clinical Development Officer Conference Call Participants Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Conference Call February 21, 2024 11:30 AM ET Brett Monia - Chief Executive Officer Richard Geary - Chief Development Officer Beth Hougen - Chief Financial Officer Eric Swayze - Executive Vice President, Research Onaiza Cadoret - Chief Global Product Strategy and Operations Officer Ja ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 92.31%. A quarter ago, it was expected that this drug discovery and development company would post a loss of $1.01 per share when it actually produced a loss of $1.03, delivering a surprise of -1.98%.Over the last fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other ...

Exhibit 99.1 Ionis reports fourth quarter and full year 2023 financial results WAINUATM approved with launch underway; on track for EU and Canada approval decisions this year (1) Reconciliation of GAAP to non-GAAP basis contained later in this release. 1 Financial Highlights Recent Marketed Medicines Highlights Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, respectively Olezarsen granted Breakthrough Therapy designation by the FDA for FCS Ionis provides f ...

Ionis (IONS) recently announced that the FDA has granted orphan drug designation to its pipeline candidate, olezarsen, for the treatment of familial chylomicronemia syndrome (FCS), a rare genetic disease.The FDA’s orphan drug designation is bestowed on medicines in development for the treatment, prevention or diagnosis of a rare disease that affects fewer than 200,000 people in the United States at the time of designation. The rare disease, FCS, is characterized by extremely high triglyceride levels and rec ...

Analysts on Wall Street project that Ionis Pharmaceuticals (IONS) will announce quarterly loss of $0.78 per share in its forthcoming report, representing a decline of 110.8% year over year. Revenues are projected to reach $183.6 million, increasing 20.8% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 12.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates durin ...

CARLSBAD, Calif., Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome (FCS), a rare, genetic disease characterized by extremely elevated triglyceride levels and recurrent acute pancreatitis (AP). The FDA grants Orphan Drug designation to therapies intended for treatment, prevention or diagnos ...